A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

10.1186/s40064-015-1392-x

Saved in:

Bibliographic Details
Main Authors:	Trudeau, M.E, Chapman, J.-A.W, Guo, B, Clemons, M.J, Dent, R.A, Jong, R.A, Kahn, H.J, Pritchard, K.I, Han, L, O’Brien, P, Shepherd, L.E, Parissenti, A.M
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183739
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183739
record_format	dspace
spelling	sg-nus-scholar.10635-1837392024-11-09T10:39:39Z A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22 Trudeau, M.E Chapman, J.-A.W Guo, B Clemons, M.J Dent, R.A Jong, R.A Kahn, H.J Pritchard, K.I Han, L O’Brien, P Shepherd, L.E Parissenti, A.M DUKE-NUS MEDICAL SCHOOL 10.1186/s40064-015-1392-x SpringerPlus 4 1 631 2020-11-19T09:41:50Z 2020-11-19T09:41:50Z 2015 Article Trudeau, M.E, Chapman, J.-A.W, Guo, B, Clemons, M.J, Dent, R.A, Jong, R.A, Kahn, H.J, Pritchard, K.I, Han, L, O’Brien, P, Shepherd, L.E, Parissenti, A.M (2015). A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. SpringerPlus 4 (1) : 631. ScholarBank@NUS Repository. https://doi.org/10.1186/s40064-015-1392-x 21931801 https://scholarbank.nus.edu.sg/handle/10635/183739 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
description	10.1186/s40064-015-1392-x
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Trudeau, M.E Chapman, J.-A.W Guo, B Clemons, M.J Dent, R.A Jong, R.A Kahn, H.J Pritchard, K.I Han, L O’Brien, P Shepherd, L.E Parissenti, A.M
format	Article
author	Trudeau, M.E Chapman, J.-A.W Guo, B Clemons, M.J Dent, R.A Jong, R.A Kahn, H.J Pritchard, K.I Han, L O’Brien, P Shepherd, L.E Parissenti, A.M
spellingShingle	Trudeau, M.E Chapman, J.-A.W Guo, B Clemons, M.J Dent, R.A Jong, R.A Kahn, H.J Pritchard, K.I Han, L O’Brien, P Shepherd, L.E Parissenti, A.M A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
author_sort	Trudeau, M.E
title	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
title_short	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
title_full	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
title_fullStr	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
title_full_unstemmed	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
title_sort	phase i/ii trial of epirubicin and docetaxel in locally advanced breast cancer (labc) on 2-weekly or 3-weekly schedules: ncic ctg ma.22
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183739
_version_	1821233852168798208

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Similar Items